MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Journal of Clinical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

9,514 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
9,514 works in the cohort · of 4,299,418page 14 of 191

Labels cover 106 of 9,514 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 9,514 of 9,514 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5
Karim Fizazi, Robert J. Jones, Stéphane Oudard, Eleni Efstathiou, Fred Saad, Ronald de Wit +14 more
2015· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
153
citations
afffundunlabeled
Prognostic Factors in Follicular Lymphoma
Thomas Relander, Nathalie A. Johnson, Pedro Farinha, Joseph M. Connors, Laurie H. Sehn, Randy D. Gascoyne
2010· review· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
151
citations
affunlabeled
Quality of Life in Long-Term Breast Cancer Survivors
Tina Hsu, Marguerite Ennis, Nicky Hood, Margaret Graham, Pamela J. Goodwin
2013· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
149
citations
affunlabeled
First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).
Martine Piccart, Andrew Holmes, José Baselga, Evandro de Azambuja, Amylou C. Dueck, Giuseppe Viale +14 more
2014· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
144
citations

How this was built: Screen · Findings · About